Value in development of a TAPIR-like mouse monoclonal antibody to Aβ

Journal of Alzheimer's Disease

Volumn 14, Issue 2, 2008, Pages 175-177

  Sambamurti, Kumar ^a   Pappolla, Miguel A ^a   Rao, K S Jagannatha ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; COPPER; EPITOPE; MEMBRANE PROTEIN; METAL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3.4A10; MONOCLONAL ANTIBODY TAPIR; ZINC;

ALZHEIMER DISEASE; BLEEDING; CELL CULTURE; DISEASE COURSE; ENERGY METABOLISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; HUMAN; IMMUNOREACTIVITY; NEUROFIBRILLARY TANGLE; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RISK FACTOR; TREATMENT FAILURE;

EID: 47849093351     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2008-14205     Document Type: Note

References (21)

1. P.A. Adlard and A.I. Bush, Metals and Alzheimer's disease, J Alzheimers Dis 10 (2006), 145-163.
2. D.A. Bennett, J.A. Schneider, R.S. Wilson, J.L. Bienias and S.E. Arnold, Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function, Arch Neurol 61 (2004), 378-384.
3. I.H. Cheng, K. Scearce-Levie, J. Legleiter, J.J. Palop, H. Gerstein, N. Bien-Ly, J. Puolivali, S. Lesne, K.H. Ashe, P.J. Muchowski and L. Mucke, Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models, J Biol Chem 282 (2007), 23818-23828.
4. K.A. Crutcher, Apolipoprotein E is a prime suspect, not just an accomplice, in Alzheimer's disease, J Mol Neurosci 23 (2004), 181-188.
5. N.C. Fox, R.S. Black, S. Gilman, M.N. Rossor, S.G. Griffith, L. Jenkins and M. Koller, Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease, Neurology 64 (2005), 1563-1572.
6. J. Hardy and D.J. Selkoe, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science 297 (2002), 353-356.
7. J. Hardy, Has the amyloid cascade hypothesis for Alzheimer's disease been proved? Curr Alzheimer Res 3 (2006), 71-73.
8. C. Hock, U. Konietzko, A. Papassotiropoulos, A. Wollmer, J. Streffer, R.C. von Rotz, G. Davey, E. Moritz and R.M. Nitsch, Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease, Nat Med 8 (2002), 1270-1275.
9. C. Hock, U. Konietzko, J.R. Streffer, J. Tracy, A. Signorell, B. Muller-Tillmanns, U. Lemke, K. Henke, E. Moritz, E. Garcia, M.A. Wollmer, D. Umbricht, D.J. de Quervain, M. Hofmann, A. Maddalena, A. Papassotiropoulos and R.M. Nitsch, Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease, Neuron 38 (2003), 547-554.
10. C. Hock and R.M. Nitsch, Clinical observations with AN-1792 using TAPIR analyses, Neurodegener Dis 2 (2005), 273-276.
11. W.L. Klein, Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets, Neurochem Int 41 (2002), 345-352.
12. S. Lesne, M.T. Koh, L. Kotilinek, R. Kayed, C.G. Glabe, A. Yang, M. Gallagher and K.H. Ashe, A specific amyloid-beta protein assembly in the brain impairs memory, Nature 440 (2006), 352-357.
13. D. Martindale, Peeling plaque. Researchers remain optimistic about a vaccine against Alzheimer's, Sci Am 286 (2002), 18, 20.
14. J.A. Nicoll, E. Barton, D. Boche, J.W. Neal, I. Ferrer, P. Thompson, C. Vlachouli, D. Wilkinson, A. Bayer, D. Games, P. Seubert, D. Schenk and C. Holmes, Abeta species removal after abeta42 immunization, J Neuropathol Exp Neurol 65 (2006), 1040-1048.
15. K. Sambamurti, N.H. Greig and D.K. Lahiri, Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease, Neuromolecular Med 1 (2002), 1-31.
16. K. Sambamurti, A. Suram, C. Venugopal, A. Prakasam, Y. Zhou, D.K. Lahiri and N.H. Greig, A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis, Curr Alzheimer Res 3 (2006), 81-90.
17. D. Schenk, Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning, Nat Rev Neurosci 3 (2002), 824-828.
18. D.J. Selkoe, Alzheimer's disease: genes, proteins, and therapy, Physiol Rev 81 (2001), 741-766.
19. E. Steen, B.M. Terry, E.J. Rivera, J.L. Cannon, T.R. Neely, R. Tavares, X.J. Xu, J.R.Wands and S.M. de la Monte, Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? J Alzheimers Dis 7 (2005), 63-80.
20. U. Thatte, AN-1792 (Elan), Curr Opin Investig Drugs 2 (2001), 663-667.
21. J. Wang, H. Hara, T. Makifuchi and T. Tabira, Development and characterization of a TAPIR-like mouse monoclonal antibody to Amyloid-β, J Alzheimers Dis 14(2) (2008) 161-173,